JUPITER NEJM PDF
The results of the Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER; number. Editorial from The New England Journal of Medicine — JUPITER Clinical Directions — Polling Results. Authors & Reviewers · Submit a Manuscript · Subscribers · Institutions · Media · Advertisers · Agents · Permissions · Reprints · NEJM Career.
|Published (Last):||4 October 2012|
|PDF File Size:||11.39 Mb|
|ePub File Size:||1.5 Mb|
|Price:||Free* [*Free Regsitration Required]|
The rosuvastatin group did not have a significant increase in myopathy or cancer but did have a higher incidence of physician-reported diabetes.
JUPITER trial – Wikipedia
In this trial of apparently healthy persons without hyperlipidemia but with elevated high-sensitivity C-reactive protein levels, rosuvastatin significantly reduced the incidence of major cardiovascular events. The trial analyzed 17, patients without evidence of heart disease but with high Juoiter levels.
We randomly assigned 17, apparently healthy men and women with low-density lipoprotein LDL cholesterol levels of less than mg per deciliter 3.
Cardiovascular Quality and Outcomes. Retrieved from ” https: The rates of the primary end point were 0.
The article’s authors critiqued what they saw as flaws in the trial, pointing out neum the cardiovascular mortality rate and the case-fatality rate for myocardial infarction were much lower than they expected. From Wikipedia, the free encyclopedia. The trial focused on patients with normal low-density lipoprotein LDL cholesterol levels but increased levels of high-sensitivity C-reactive protein hs-CRP.
The trial was stopped after a median follow-up of 1.
Consistent effects were observed in all subgroups evaluated. Am J Kidney Dis.
Nejk levels of the inflammatory biomarker high-sensitivity C-reactive protein predict cardiovascular events.
An I ntervention T rial E valuating R osuvastatin trial was a clinical trial aimed at evaluating whether statins reduce heart attacks and strokes in people with normal cholesterol levels.
N Engl J Med. The trial was sponsored by AstraZenecathe marketer of Crestor rosuvastatin. Jupter the uupiter of C-reactive protein, a study employing Mendelian randomizationpublished in the Journal of the American Medical Association suggested that CRP does not play a causal role in cardiovascular disease; the results may argue against CRP’s use as a marker of cardiovascular disease risk or for identifying subjects for statin therapy as in JUPITER, and more strongly argue against using CRP as a therapeutic target per se.
Comment in Ann Intern Med. Cleve Clin J Med.
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.
The trial was stopped early, after just 1. They also raised concerns about conflict of interest in the trial design juipter leadership: They concluded that, kupiter results of the trial do not support the use of statin treatment for primary prevention of cardiovascular diseases and raise troubling questions concerning the role of commercial sponsors.
Compared to patients taking a placebopatients given rosuvastatin jupiyer reductions in LDL and CRP levels, and a reduction of 0. Clinical trials related to cardiology Clinical trials sponsored by AstraZeneca Statins. Results, Controversies, and Implications for Prevention”. JUPITER was a randomized double-blind placebo-controlled study investigating the use of rosuvastatin in the primary prevention of cardiovascular disease.
Because half of all vascular events occur in patients with normal or low levels of LDL cholesterol, JUPITER was nemj to determine whether hs-CRP testing could identify these patients, and whether statin therapy could prevent cardiovascular events among them.
There were no significant differences between the treatment groups with respect to muscle pain, muscle weakness, hepatic function, or renal function; however, the researchers noted small but statistically juiter increases in the rate of physician-reported diabetes and glycated hemoglobin values in the rosuvastatin group, an effect that has also been seen in studies with other statins. Since statins lower levels of high-sensitivity C-reactive protein as well as cholesterol, we hypothesized that people with elevated high-sensitivity C-reactive protein levels but without hyperlipidemia might benefit from statin treatment.
Views Read Edit View history. Michel de Lorgeril, et al.